• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Dexilant (dexlansoprazole) delayed release capsule

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2010

Summary View

ADVERSE REACTIONS

Additional adverse reactions that were reported in a long-term uncontrolled study and were considered related: bursitis

DRUG INTERACTIONS

Tacrolimus
  • Concomitant administration of dexlansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.